{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:25:16Z","timestamp":1781360716605,"version":"3.54.1"},"reference-count":34,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,6,15]]},"DOI":"10.2169\/internalmedicine.0815-22","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T22:10:15Z","timestamp":1667340615000},"page":"1715-1722","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center"],"prefix":"10.2169","volume":"62","author":[{"given":"Yosuke","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kaneyama","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 172: 867-877, 2015.","DOI":"10.1111\/bjd.13717"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 30: 224-232, 2002.","DOI":"10.1016\/S0923-1811(02)00109-3"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 381: 320-332, 2013.","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fania L, Di Zenzo G, Didona B, et al. Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. J Eur Acad Dermatol Venereol 32: e153-e154, 2018.","DOI":"10.1111\/jdv.14649"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131: 637-643, 2011.","DOI":"10.1038\/jid.2010.301"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Liu SD, Chen WT, Chi CC. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol 156: 891-900, 2020.","DOI":"10.1001\/jamadermatol.2020.1587"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Pasmatzi E, Monastirli A, Habeos J, et al. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 34: e133, 2011.","DOI":"10.2337\/dc11-0804"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Aouidad I, Fite C, Marinho E, et al. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 149: 243-245, 2013.","DOI":"10.1001\/jamadermatol.2013.1073"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Attaway A, Mersfelder TL, Vaishnav S, et al. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 8: 24-28, 2014.","DOI":"10.3315\/jdcr.2014.1166"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. B\u00e9n\u00e9 J, Jacobsoone A, Coupe P, et al. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol 29: 112-114, 2015.","DOI":"10.1111\/fcp.12083"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol 152: 224-226, 2016.","DOI":"10.1001\/jamadermatol.2015.2939"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Mendon\u00e7a FM, Mart\u00edn-Gutierrez FJ, R\u00edos-Mart\u00edn JJ, et al. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin. Dermatology 232: 249-253, 2016.","DOI":"10.1159\/000443330"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakai A, Shimomura Y, Ansai O, et al. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180. Br J Dermatol 176: 541-543, 2017.","DOI":"10.1111\/bjd.15111"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yoshiji S, Murakami T, Harashima SI, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases. J Diabetes Investig 9: 445-447, 2018.","DOI":"10.1111\/jdi.12695"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. B\u00e9n\u00e9 J, Moulis G, Bennani I, et al; French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database. Br J Dermatol 175: 296-301, 2016.","DOI":"10.1111\/bjd.14601"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Garc\u00eda M, Aranburu MA, Palacios-Zabalza I, et al. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 41: 368-370, 2016.","DOI":"10.1111\/jcpt.12397"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Arai M, Shirakawa J, Konishi H, et al. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database. Diabetes Care 41: e130-e132, 2018.","DOI":"10.2337\/dc18-0210"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13: 7-18, 2011.","DOI":"10.1111\/j.1463-1326.2010.01306.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging 31: 203-214, 2014.","DOI":"10.1007\/s40266-014-0155-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig 7 Suppl 1: 102-109, 2014.","DOI":"10.1111\/jdi.12490"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care 37: 1367-1374, 2014.","DOI":"10.2337\/dc13-2289"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Murakami T, Yabe D, Inagaki N. Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: clinical features and pathophysiology. J Diabetes Investig 10: 1168-1170, 2019.","DOI":"10.1111\/jdi.13060"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 136: 2201-2210, 2016.","DOI":"10.1016\/j.jid.2016.06.622"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Horikawa H, Kurihara Y, Funakoshi T, et al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol 178: 1462-1463, 2018.","DOI":"10.1111\/bjd.16479"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol 138: 1201-1204, 2018.","DOI":"10.1016\/j.jid.2017.11.023"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Chijiwa C, Takeoka S, Kamata M, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. J Dermatol 45: 596-599, 2018.","DOI":"10.1111\/1346-8138.14245"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 66: 479-485, 2012.","DOI":"10.1016\/j.jaad.2011.06.032"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Invest 5: 581-587, 2014.","DOI":"10.1111\/jdi.12183"},{"key":"29","unstructured":"29. Fukumoto Y, Oishi M, Arai K, et al. Clinical characteristics and treatment of patients with diabetes mellitus over 60 years of age (cross-sectional survey with JDDM data). J Jpn Diabetes Soc 63: 179-187, 2020."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Varpuluoma O, F\u00f6rsti AK, Jokelainen J, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol 138: 1659-1661, 2018.","DOI":"10.1016\/j.jid.2018.01.027"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Douros A, Rouette J, Yin H, et al. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care 42: 1496-1503, 2019.","DOI":"10.2337\/dc19-0409"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Hung CT, Liu JS, Cheng CY, et al. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, population-based, cohort study in Taiwan. J Dermatol 47: 245-250, 2020.","DOI":"10.1111\/1346-8138.15195"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol 10: 787-812, 2014.","DOI":"10.1517\/17425255.2014.907274"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Okondo MC, Johnson DC, Sridharan R, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol 13: 46-53, 2017.","DOI":"10.1038\/nchembio.2229"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/12\/62_0815-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T03:27:28Z","timestamp":1686972448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/12\/62_0815-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0815-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"0815-22"}}